A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Ligelizumab (Primary) ; Omalizumab
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Novartis
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2017 This trial has been completed in Greece. (end date: 2017-06-12)
- 15 Jun 2017 This trial has been completed in Spain.